|
Alkermes plc (ALKS) DCF Valuation
IE | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Alkermes plc (ALKS) Bundle
Evaluate Alkermes plc's financial outlook like an expert! This (ALKS) DCF Calculator provides you with pre-filled financial data and the complete flexibility to modify revenue growth, WACC, margins, and other essential assumptions to align with your projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,038.8 | 1,173.8 | 1,111.8 | 1,663.4 | 1,557.6 | 1,756.1 | 1,979.9 | 2,232.2 | 2,516.7 | 2,837.4 |
| Revenue Growth, % | 0 | 13 | -5.28 | 49.61 | -6.36 | 12.74 | 12.74 | 12.74 | 12.74 | 12.74 |
| EBITDA | -6.0 | 176.4 | 59.8 | 519.5 | 420.6 | 274.2 | 309.1 | 348.5 | 392.9 | 443.0 |
| EBITDA, % | -0.57992 | 15.03 | 5.38 | 31.23 | 27 | 15.61 | 15.61 | 15.61 | 15.61 | 15.61 |
| Depreciation | 81.9 | 78.7 | 77.9 | 74.9 | .0 | 91.6 | 103.3 | 116.5 | 131.3 | 148.0 |
| Depreciation, % | 7.88 | 6.7 | 7 | 4.5 | 0 | 5.22 | 5.22 | 5.22 | 5.22 | 5.22 |
| EBIT | -87.9 | 97.7 | -18.1 | 444.6 | 420.6 | 182.5 | 205.8 | 232.0 | 261.6 | 294.9 |
| EBIT, % | -8.46 | 8.33 | -1.63 | 26.73 | 27 | 10.39 | 10.39 | 10.39 | 10.39 | 10.39 |
| Total Cash | 659.8 | 765.7 | 740.1 | 773.5 | 751.7 | 1,018.8 | 1,148.7 | 1,295.0 | 1,460.1 | 1,646.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 289.5 | 326.6 | 296.9 | 333.2 | 384.5 | 446.5 | 503.4 | 567.5 | 639.8 | 721.4 |
| Account Receivables, % | 27.87 | 27.82 | 26.7 | 20.03 | 24.69 | 25.42 | 25.42 | 25.42 | 25.42 | 25.42 |
| Inventories | 125.7 | 150.3 | 181.4 | 186.4 | 182.9 | 225.4 | 254.1 | 286.5 | 323.0 | 364.2 |
| Inventories, % | 12.1 | 12.81 | 16.32 | 11.21 | 11.74 | 12.84 | 12.84 | 12.84 | 12.84 | 12.84 |
| Accounts Payable | 46.0 | 55.7 | 32.8 | 65.6 | 45.6 | 66.8 | 75.3 | 84.9 | 95.7 | 107.9 |
| Accounts Payable, % | 4.43 | 4.75 | 2.95 | 3.95 | 2.93 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 |
| Capital Expenditure | -42.2 | -29.0 | -38.3 | -48.0 | -33.5 | -52.7 | -59.5 | -67.0 | -75.6 | -85.2 |
| Capital Expenditure, % | -4.06 | -2.47 | -3.44 | -2.89 | -2.15 | -3 | -3 | -3 | -3 | -3 |
| Tax Rate, % | 17.28 | 17.28 | 17.28 | 17.28 | 17.28 | 17.28 | 17.28 | 17.28 | 17.28 | 17.28 |
| EBITAT | -100.9 | 119.8 | -17.1 | 375.2 | 348.0 | 168.6 | 190.0 | 214.3 | 241.6 | 272.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -430.5 | 117.5 | -1.8 | 393.6 | 246.6 | 124.1 | 156.8 | 176.8 | 199.3 | 224.7 |
| WACC, % | 6.49 | 6.49 | 6.47 | 6.43 | 6.42 | 6.46 | 6.46 | 6.46 | 6.46 | 6.46 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 720.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 229 | |||||||||
| Terminal Value | 5,141 | |||||||||
| Present Terminal Value | 3,760 | |||||||||
| Enterprise Value | 4,481 | |||||||||
| Net Debt | -216 | |||||||||
| Equity Value | 4,697 | |||||||||
| Diluted Shares Outstanding, MM | 169 | |||||||||
| Equity Value Per Share | 27.76 |
What You Will Gain
- Authentic Alkermes Data: Preloaded financials – including revenue and EBIT – derived from actual and projected figures.
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- Immediate Valuation Adjustments: Automatic recalculations to assess the impact of changes on Alkermes' fair value.
- Flexible Excel Template: Designed for quick modifications, scenario analysis, and detailed forecasts.
- Efficient and Precise: Bypass the hassle of building models from the ground up while ensuring accuracy and adaptability.
Key Features
- Accurate Alkermes Financial Data: Gain access to reliable historical data and future estimates tailored for Alkermes plc (ALKS).
- Flexible Forecast Inputs: Modify highlighted fields such as WACC, growth rates, and profit margins to suit your analysis.
- Real-Time Calculations: Enjoy automatic recalculations of DCF, Net Present Value (NPV), and cash flow metrics.
- User-Friendly Dashboard: Intuitive charts and summaries to help you easily interpret your valuation findings.
- Designed for All Skill Levels: A straightforward and accessible layout ideal for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the prebuilt Excel template featuring Alkermes plc's (ALKS) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view the recalculated results, including Alkermes plc's (ALKS) intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or generate comprehensive reports.
Why Choose This Calculator?
- Accurate Data: Real Alkermes plc (ALKS) financials provide dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Ready-made calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: An intuitive design and clear, step-by-step guidance make it accessible for all users.
Who Should Use Alkermes plc (ALKS)?
- Investors: Gain insights and make informed decisions with a comprehensive analysis of Alkermes plc (ALKS).
- Financial Analysts: Utilize detailed reports and data to streamline your financial assessments of Alkermes plc (ALKS).
- Consultants: Tailor your presentations or recommendations with up-to-date information on Alkermes plc (ALKS).
- Healthcare Enthusiasts: Explore the pharmaceutical landscape and enhance your knowledge of Alkermes plc (ALKS) and its products.
- Educators and Students: Incorporate real-world case studies of Alkermes plc (ALKS) into your finance and healthcare curriculum.
What the Template Contains
- Historical Data: Includes Alkermes plc’s (ALKS) past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Alkermes plc’s (ALKS) intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital specific to Alkermes plc (ALKS).
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions for Alkermes plc (ALKS).
- Quarterly and Annual Statements: A complete breakdown of Alkermes plc’s (ALKS) financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically for Alkermes plc (ALKS).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.